Mosaic Therapeutics combines advanced computational methods with large‑scale experimental approaches to identify and develop targeted oncology therapies for biomarker‑stratified populations. The company applies research from co‑founder Dr Mathew Garnett’s Translational Cancer Genomics Laboratory and maintains a bespoke relationship with the Wellcome Sanger Institute, giving it access to deep scientific expertise and biological assets. Mosaic’s lead programmes are being advanced through preclinical development toward IND‑enabling studies. The Series A financing will support progression of the pipeline and recruitment across senior leadership, experimental biology, and computational teams. The company was co‑founded by Dr Mathew Garnett, Professor Emile Voest, and Dr Adrian Ibrahim, and recently appointed Brian Gladsden as CEO. Mosaic positions its platform to discover therapies for molecularly defined patients in cancer indications with high unmet need.

Total raised

$28M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2023